Clinical Trials Directory

Trials / Completed

CompletedNCT01288352

Early Treatment of Atrial Fibrillation for Stroke Prevention Trial

Early Therapy of Atrial Fibrillation for Stroke Prevention Trial (EAST).

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
2,789 (actual)
Sponsor
Atrial Fibrillation Network · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

EAST prospectively tests the hypothesis that an early, structured rhythm control therapy based on antiarrhythmic drugs and catheter ablation can prevent atrial fibrillation (AF) related complications in patients with AF when compared to usual care. Patients will be randomized to early therapy or usual care. In the early therapy group, patients will receive either catheter ablation (usually by pulmonary vein isolation), or adequate antiarrhythmic drug therapy at an early time point. The initial therapy will be selected by the local investigator. Upon AF recurrence, both modalities will be combined. Usual care will be conducted following the 2010European Society of Cardiology ( ESC )guidelines for AF treatment. Early rhythm control therapy will be guided by Electrocardiogram (ECG) monitoring.

Conditions

Interventions

TypeNameDescription
OTHERearly standardised rhythm controlPatients in the early therapy group will be treated following the same therapeutic recommendations of the ESC guidelines as the usual care group. In addition, rhythm control therapy will be initiated early with the aim of preventing recurrence and delaying or preventing progression of AF. Early-onset rhythm control therapy can consist of: 1. Optimal antiarrhythmic drug therapy 2. Catheter ablation with the aim of pulmonary vein isolation (PVI), 3. Antiarrhythmic drug therapy and catheter ablation may be combined and supplemented by early cardioversion in patients with persistent AF. All individual treatment decisions will be taken by the treating study physician considering the labelling of the procedures and drugs and patient preferences.

Timeline

Start date
2011-07-01
Primary completion
2020-03-06
Completion
2020-05-31
First posted
2011-02-02
Last updated
2020-07-23

Locations

11 sites across 11 countries: Belgium, Czechia, Denmark, France, Germany, Italy, Netherlands, Poland, Spain, Switzerland, United Kingdom

Source: ClinicalTrials.gov record NCT01288352. Inclusion in this directory is not an endorsement.